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Objective: To explore how neonates with respiratory failure are selected for
extracorporeal membrane oxygenation (ECMO) once severity of illness
criteria are met, and to determine how conﬂicts between ECMO providers
and parents over the initiation of ECMO are addressed.
Study Design: A cross-sectional study was conducted using a data
collection survey, which was sent to the directors of neonatal respiratory
ECMO centers.
Result: The lowest birth weight and gestational age at which respondents
would consider placing a neonate on ECMO were frequently below
recommended thresholds. There was wide variability in respondents’
willingness to place neonates on ECMO in the presence of conditions such
as intraventricular hemorrhage and hypoxic ischemic encephalopathy.
The number of respondents who would never seek to override parental
refusal of ECMO was equal to the number who would always do so.
Conclusion: Signiﬁcant variability exists in the selection criteria for
neonatal ECMO and in how conﬂicts with parents over the provision of
ECMO are resolved.
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Introduction
The ﬁrst successful use of extracorporeal membrane oxygenation
(ECMO) to treat a neonate with meconium aspiration syndrome
was reported by Bartlett et al., in 1976.
1 Since then ECMO has
become an accepted treatment for neonates with respiratory failure
due to a variety of causes that fail ‘conventional’ management.
More than 22000 neonates with respiratory failure treated with
ECMO have been reported to the Extracorporeal Life Support
Organization (ELSO) International Registry as of January 2009.
2
Determining which neonates are likely to beneﬁt from ECMO
and are appropriate candidates for ECMO is difﬁcult. This is
because of an expanding choice of non-ECMO therapies for
respiratory failure in term neonates, signiﬁcant advances in ECMO
technology, and limited data regarding the relative risks and
beneﬁts of these therapies. Measures of the severity of illness such
as the oxygenation index and the alveolar–arterial oxygen
gradient are fairly well standardized as indicators for initiating
ECMO after the failure of optimal non-ECMO support. Other
criteria are also used in patient selection. These include, for
example, birth weight and gestational age, markers of reversibility
of the underlying disease process, indicators of the risk of bleeding
while on ECMO and predictors of long-term neurodevelopmental
impairment. The most recent guidelines for these other general
criteria were published by ELSO in 2005
3 (Table 1).
These criteria are meant to serve only as a guide, and the
speciﬁc selection criteria used by individual ECMO centers are
unknown. We investigated how ECMO centers in the United
States and abroad are determining patient eligibility for neonatal
ECMO once severity of illness criteria have been met. We also
investigated how disagreements between families and ECMO
providers regarding the initiation of ECMO support are approached
by providers.
Methods
An electronic survey instrument was designed to explore the patient
selection process for ECMO to treat neonatal respiratory failure. The
survey consisted of 14 questions (including three multipart
questions) related to patient selection and nine demographic
questions about the respondents and their ECMO centers.
The survey was sent to all active neonatal ECMO centers that
were members of ELSO, which includes all international centers
that have submitted data from any neonatal respiratory subjects
over the past 5 years. Surveys were addressed to the medical
director of the ECMO program, or to the assistant or associate
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The survey was initially distributed through the ELSO Monthly
Newsletter in February 2008, followed by two additional electronic
invitations.
4 Surveys were received through May 2008.
Data were imported into a separate database and analyzed using
SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Owing to the categorical
nature of the variables collected in the survey, histograms and
frequency distributions were used to describe each variable.
Categorical variables with under-represented levels were collapsed
such that some of the ordinal categorical variables became
dichotomous. Study results were summarized with frequencies,
percents, pie-charts and bar graphs. We conducted bivariate analyses
for categorical variables using w
2 or Fisher’s exact test. A two-sided
a of 0.05 was used to establish the statistical signiﬁcance.
The study protocol was submitted to the Yale University School
of Medicine Human Investigation Committee and met the criteria
for exemption from committee review.
Results
Description of the study sample
Responses were received from 81 of 124 (65%) active neonatal
respiratory ECMO centers. Of the respondents, 53% identiﬁed
themselves as neonatologists, 23% as pediatric intensive care
physicians and 18% as surgeons. A total of 52% of respondents
were male and 48% were female. A total of 20% of respondents
were 40 years old or younger, 49% were 41 to 50 years old and
27% were 51 to 60 years old. The majority of respondents came
from the North American (84%) and the European (12%) ECMO
centers. The majority of respondents described their institution
as an academic medical center (70%) or a hospital afﬁliated
with an academic medical center (20%). Most ECMO centers
(87%) had been in operation for >10 years. Regarding patient
volume, 78% of respondents reported their center’s current average
yearly number of non-congenital diaphragmatic hernia (CDH)
neonatal respiratory patients as p10, and 43% as p5. A total
of 96% of respondents reported their center’s current average yearly
number of CDH patients as p10, and 70% as p5.
General method for making decisions regarding ECMO
candidacy
When confronted with patients for whom ECMO candidacy is
unclear, 87% of respondents usually or always rely on a consensus
opinion of the ECMO team members to make their decisions.
A total of 54% of respondents utilize phone consultation with other
ECMO centers at least sometimes. Only one-quarter of respondents
stated that determining ECMO candidacy in this setting is usually
or always an individual physician’s decision (Table 2).
ECMO candidacy and gestational age/birth weight
Respondents were asked the lowest gestational age and birth weight
at which they would consider placing a neonate on ECMO. A total of
31% of respondents set 33 completed weeks of gestation or lower as their
lowest gestational age (Figure 1a). A total of 23% of respondents reported
that they had actually placed a neonate with a gestational age
<34 weeks on ECMO and 5% of respondents reported having placed
a neonate with a gestational age <32 weeks on ECMO. A total of 65% of
respondents would consider neonates with birth weights <2000g as
potential ECMO candidates, and 15% would consider neonates with birth
weights <1800g as potential ECMO candidates (Figure 1b).
Respondents from centers with 15 or fewer non-CDH cases
per year were more likely to set 33 completed weeks of gestation
or lower as their lowest gestational age for ECMO candidacy
than were respondents from centers with more than
15 non-CDH cases per year, although the difference was not
statistically signiﬁcant (34 vs 11%, P¼0.26). Of the respondents
from centers with more than 15 non-CDH cases per year, one
Table 1 General neonatal ECMO criteria
Gestational age X34 weeks or birth weight X2000g
No signiﬁcant coagulopathy or uncontrolled bleeding
No major intracranial hemorrhage
Reversible lung disease with length of mechanical ventilation <10–14 days
No uncorrectable congenital heart disease
No lethal congenital anomalies
No evidence of irreversible brain damage
Modiﬁed with permission from Van Meurs et al.
3
Table 2 Approach to neonatal ECMO decision making
Response to survey question, ‘When confronted with patients for whom ECMO candidacy is unclear, how often have you used the
following approaches in decision making?’
Never Rarely Sometimes Usually Always
Individual ECMO physician’s decision 18 33 24 16 9
ECMO/Neonatology team group consensus 0 1 12 58 30
Ethics consultation 42 36 21 1 0
Phone consultation with other ECMO centers 15 31 41 9 4
Values expressed as percentages.
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35 weeks gestation as the lowest gestational age for ECMO
candidacy. There was no signiﬁcant difference between the
percentage of neonatologists and non-neonatologists who identiﬁed
33 weeks gestation or lower as the lowest gestational age for ECMO
candidacy. Respondents were signiﬁcantly more likely to pick a
lowest birth weight below 2000g than they were to pick a lowest
gestational age below 34 weeks for ECMO candidacy (65 vs 31%,
P<0.0001).
ECMO candidacy and speciﬁc co-morbidities
Respondents were asked how often neonates who met severity of
illness criteria would be offered ECMO in the presence of speciﬁc
co-morbidities, such as sepsis with uncontrolled disseminated
intravascular coagulation, grade II intraventricular hemorrhage,
mechanical ventilation for more than 14 days and moderate
hypoxic ischemic encephalopathy. In the presence of any one of
these conditions, at least one-quarter of respondents stated that
they would never or rarely offer ECMO and at least one-quarter
of respondents stated that they would always or usually offer
ECMO (Figure 2). Other conditions were considered absolute
contraindications to ECMO by a large percentage of respondents.
For patients who otherwise meet ECMO criteria, 91% of respondents
would never offer ECMO to a neonate with Trisomy 13, 90% would
never offer ECMO to a neonate with Trisomy 18, 73% would never
offer ECMO to a neonate with grade III or grade IV intraventricular
hemorrhage and 48% would never offer ECMO to a neonate with
severe hypoxic ischemic encephalopathy.
Trisomy 21 was considered an absolute contraindication to
ECMO by only 3% of respondents; 68% of respondents would
usually or always offer ECMO to neonates with Trisomy 21 who
otherwise meet ECMO criteria.
ECMO candidacy and conﬂicts in decision making between
family members and healthcare providers
When presented with a scenario in which parents refused to give
consent for ECMO for a neonate with respiratory failure whom the
respondent felt was likely to survive bypass with a favorable
neurodevelopmental outcome, 22% of respondents stated they
would never seek to override parental refusal of ECMO, whereas an
equal percentage said they would always do so (Figure 3). In fact,
15% of respondents reported that they had initiated ECMO at least
once despite parental objection. Respondents were signiﬁcantly
more likely to override parental refusal of ECMO for meconium
aspiration syndrome than they were for CDH (60 vs 16%,
P<0.0001). Respondents who are neonatologists were signiﬁcantly
more likely to override parental refusal of ECMO for meconium
aspiration syndrome than were other respondents (82 vs 41%,
P¼0.0003).
On the other side of the potential conﬂict between physicians and
parents regarding the use of ECMO, 57% of respondents reported
that they had refused to provide ECMO to a child whose parents
requested this therapy. A total of 46% of respondents reported that
they had treated a child with ECMO whom they felt was not an
appropriate candidate, because of strong parental request to do so.
Interpretation of the literature regarding the efﬁcacy of ECMO
When asked why they use ECMO to treat non-CDH patients who fail
conventional therapy, 54% of respondents stated that the literature
has shown with a high degree of certainty, and 44% with a
moderate degree of certainty that ECMO signiﬁcantly improves the
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Figure 1 (a) Responses to the survey question, ‘What is the lowest gestational
age that you would consider placing a neonate on ECMO?’ Answer choices are
identiﬁed with associated shading. Percentages of responses are shown in the
pie-chart. (b) Responses to the survey question, ‘What is the lowest birth weight,
assuming that the patient meets your minimum gestational age requirements, that
you would consider placing a neonate on ECMO?’ Answer choices are identiﬁed
with associated shading. Percentages of responses are shown in the pie-chart.
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Journal of Perinatologysurvival of these patients. When asked why they use ECMO to treat
CDH patients who fail conventional therapy, 5% of respondents
stated that the literature has shown with a high degree of certainty,
and 34% with a moderate degree of certainty that ECMO
signiﬁcantly improves the survival of these patients. A total of 61%
of respondents stated that the literature provides weak evidence that
ECMO improves the survival of neonates with CDH, but use ECMO
because they believe it improves survival or that it should be offered
as a treatment of ‘last resort’.
Discussion
The selection of appropriate neonates with respiratory failure for
ECMO support is based on the severity of illness and other criteria.
Three small-randomized trials conducted in the United States
5–7
and one larger trial conducted in the United Kingdom
8 showed that
ECMO, or a policy of referral for ECMO, improves survival of
neonates with respiratory failure. Patients were enrolled in these
studies if they were felt to have a high likelihood of mortality with
continued non-ECMO management, and if they met other ECMO
eligibility criteria. A high likelihood of mortality was usually based
on measures of illness severity such as the ratio of arterial to
alveolar partial pressure of oxygen, the alveolar–arterial oxygen
gradient or the oxygenation index. The oxygenation index and
other severity of illness criteria are limited in their ability to predict
mortality,
9 particularly as the non-ECMO management of neonates
with respiratory failure has evolved. These severity of illness criteria
for ECMO may need to be updated,
10–13 particularly for neonates
with CDH,
14–16 but at the moment are fairly well standardized.
Our survey addressed other criteria used to determine ECMO
eligibility. We found that there is signiﬁcant variation between ECMO
centers, and signiﬁcant deviation from the published ELSO guidelines,
regarding patient selection on the basis of these criteria. This variability
is not surprising and potentially has many explanations. Neonates with
respiratory failure are a heterogeneous group of patients, and ECMO is
provided by a variety of caregivers, in diverse settings, and at centers
with varying ECMO experience. A total of 43% of the ECMO centers
participating in our survey treat an average of ﬁve or fewer non-CDH
cases per year. Finally, ECMO and its alternative therapies are
continuously evolving, and there are limited and at times conﬂicting
data regarding the relative efﬁcacy, complications and long-term
outcomes associated with these therapies.
The willingness of many survey respondents to offer ECMO
to smaller and less-mature babies, for example, comes in the face
of conﬂicting data regarding the added risk these babies face
on ECMO,
17–22 and is fostered by improvements in ECMO
technology that decrease the risk of bleeding and allow
cannulation of smaller vessels. Different birth weight and
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Figure 2 Responses to the survey question, ‘Assuming a patient has failed conventional therapy, meets your criteria for ECMO, and has no other potential
contraindications, how often would you offer ECMO if the following conditions were present?’ Answer choices are ‘Never’, ‘Rarely’, ‘Sometimes’, ‘Usually’, or ‘Always’.
Answer choices for each of four conditions are presented on the x axis, percentage of responses within each condition on the y axis.
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Figure 3 Responses to the survey question, ‘How often would you seek to
override parental refusal of ECMO for respiratory failure if you believe the neonate
is likely to survive ECMO with a favorable neurodevelopmental outcome?’ Answer
choices are presented on the x axis, percentage of responses on the y axis.
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differences in adoption of these technologies or different levels
of comfort and experience. Note, however, that centers with
higher ECMO case loads tended to maintain higher minimum
gestational age thresholds.
The wide range in respondents’ willingness to provide ECMO in
the face of relative contraindications, such as coagulopathy,
intraventricular hemorrhage, prolonged ventilation and hypoxic
ischemic encephalopathy may similarly be due to different levels of
comfort and experience between ECMO centers. Other potential
factors are the difﬁculty and variability in deﬁning several
conditions (such as ‘irreversible’ lung disease), the uncertain
prognostic signiﬁcance of other conditions (such as grade II
intraventricular hemorrhage or moderate hypoxic ischemic
encephalopathy) and the varying degrees of severity and potential
reversibility of other conditions (such as sepsis and disseminated
intravascular coagulation). However, even co-morbidities that are
easily deﬁned, convey a consistently poor prognosis, and are
irreversible, such as Trisomy 18 and Trisomy 13, do not seem to be
absolute contraindications to ECMO among respondents: B10% of
respondents stated that they would offer ECMO in at least some
circumstances for patients with these conditions.
Perhaps the most striking variability among respondents was in
their willingness to initiate ECMO for neonates who meet ECMO
criteria, are expected to survive ECMO with a favorable
neurodevelopmental outcome, but whose parents refuse ECMO
support. This variability may be because of differences in clinical
experience, differences in personal values with regard to parental
authority versus the newborn’s right to treatment or other factors.
The fact that neonatologists were more than twice as likely as non-
neonatologists to state that they would override parental refusal of
ECMO for neonates with meconium aspiration syndrome who were
considered appropriate ECMO candidates may reﬂect some of these
differences.
The willingness of respondents to initiate ECMO over parental
objection was also shown to depend on the cause of the respiratory
failure. Koogler and Lantos
23 have noted that in the past
physicians’ reticence to override parental refusal of ECMO may
have been appropriate because of uncertain ECMO survival rates,
the perceived burdens of ECMO, and the uncertain long-term
sequelae of ECMO, but that the 94% survival rate for babies in the
ELSO Registry with meconium aspiration who received ECMO may
‘ycreate a moral obligation for doctors to seek court approval to
override parental refusals.’ A total of 60% of respondents stated that
they would override parental refusal of ECMO for meconium
aspiration syndrome; respondents’ willingness to override parental
refusal may be mitigated by their interpretation of the literature
regarding ECMO’s efﬁcacy compared with ‘conventional’ therapy.
The clinical trials of neonatal ECMO conducted in the United States
randomized a total of 59 patients, most of who were treated before
1990, and two of the studies used non-conventional randomization
strategies. The United Kingdom ECMO trial enrolled 185 patients
using a conventional randomization strategy, and included
follow-up to age of 7 years.
24 However, relatively few patients
receiving conventional management in that study were treated with
inhaled nitric oxide, high-frequency ventilation or surfactant (12,
15 and 40%, respectively), and it is not clear whether the study’s
results would be replicated in the setting of current non-ECMO
care. Only 54% of respondents to our survey felt that the literature
has shown with a high degree of certainty that ECMO signiﬁcantly
improves survival in non-CDH patients.
There have been no randomized trials showing that ECMO
improves survival of neonates with CDH, and only 5% of respondents
felt that the literature has shown with a high degree of certainty that
ECMO signiﬁcantly improves survival of these patients. This may
partly explain why only 16% of respondents would initiate ECMO over
parental refusal for neonates with CDH. Not surprisingly, respondents
w h of e l tt h a tt h el i t e r a t u r eh a ss h own with a high or moderate degree
of certainty that ECMO signiﬁcantly improves survival of patients with
CDH were more likely to initiate ECMO over parental refusal than
were respondents who felt the literature provided weak evidence of this
beneﬁt (27 vs 9%, P¼0.055). Differences in the perceived amount
of suffering associated with treatment, and in short- and long-term
morbidities, may also explain the difference in approach to parental
refusal of ECMO support for neonates with meconium aspiration
versus those with CDH.
The results of this survey provide insight into the practices
of two-thirds of the ECMO centers that are members of ELSO
regarding the selection of neonates for ECMO once it is determined
that severity of illness criteria have been met. The difﬁculty
in determining ECMO eligibility is likely reﬂected in the small
percentage of respondents who stated that difﬁcult decisions
regarding ECMO candidacy are usually or always an individual
ECMO physician’s decision. Most often these decisions are made by
a consensus of ECMO team members, and not infrequently after
telephone consultation with other ECMO centers.
The results of this survey allow ECMO centers to determine how
their criteria to determine neonatal ECMO eligibility compare with
those of other centers. The results may also help physicians at
institutions that do not provide ECMO decide which patients should
be referred to an ECMO center. The results of this survey provide a
‘snapshot’ of respondents’ views regarding the ECMO eligibility in
2008, but do not provide insight into how these perceptions may
have changed over time. For example, the current willingness of
respondents to consider patients with Trisomy 21 eligible for ECMO
probably developed over time as attitudes regarding the care of
patients with Trisomy 21 evolved and experience placing these
patients on ECMO was gained.
25
This survey is limited in that respondents had to answer
questions about clinical scenarios without being provided
additional information that may have modiﬁed their responses.
There may have been differences in how respondents interpreted
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for him or herself, and responses may not reﬂect the opinions or
practice of other members of the ECMO center. Finally, one-third of
ECMO centers contacted did not participate in the survey, and thus
their practices are not reﬂected in these data. Although the
geographic distribution of respondents to our survey was very
similar to the distribution of ELSO member centers, we cannot be
sure how representative our sample was of the entire ELSO
population regarding other parameters. Nonetheless, our survey
reﬂects the opinions of over 80 ECMO clinicians practicing in the
United States and abroad in a variety of clinical settings.
In conclusion, the results of this survey show that there is
signiﬁcant variability between respondents in how neonates are
selected for ECMO once severity of illness criteria have been met.
There is also variability in how respondents address conﬂicts
between parents and the ECMO team regarding the initiation of
ECMO. It is hoped that these ﬁndings will be helpful to ECMO and
non-ECMO clinicians, and stimulate further discussion and
continued investigations regarding patient selection for neonatal
ECMO. Patient eligibility criteria for ECMO can be expected
to evolve as advances are made in ECMO technology and in
non-ECMO care, as additional information regarding patient
outcomes becomes available, and as ethical issues relevant
to patient selection are addressed.
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